1
|
Ebrahimi PS, Bala MA, Tafreshi ZM, Piroti H, Mostafaei M, Ghahremani B, Shaverdi F, Porshokouh AI, Deravi N, Poudineh M, Roostaie M. Maternal occupational exposure to asthmogenic during pregnancy and the future risk of asthma in children: A meta-analysis. Turk J Obstet Gynecol 2024; 21:123-130. [PMID: 38853509 DOI: 10.4274/tjod.galenos.2024.50497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2024] Open
Abstract
The association between maternal occupational exposure during pregnancy and the subsequent development of asthma in their children has always been a matter of debate, and the results of cohort studies on this issue have been controversial. The current study is the first systematic review and meta-analysis aimed at evaluating the risk of developing subsequent asthma in children based on maternal occupational exposure during the gestation period. To retrieve eligible studies, an advanced literature search was performed up to August 10, 2023 from the following databases: PubMed, Scopus, and Google Scholars. The title and abstract of related articles were screened; hence, the full texts were reviewed. Data extraction was conducted; hence, the included articles were analyzed to assess the mention association. From a total of 10 cohort studies with a total record of 5372, it was found that there is no significant relationship between occupational exposure to asthmogenic during pregnancy and later asthma in children. The pooled odds ratio of asthmatic children in patients with maternal occupational exposure to asthmogenic during pregnancy was 1.03 (95% confidence interval, 0.97-1.09) I2= 13% p=0.62. It was concluded that there is no significant association between maternal occupational exposure and future asthma in children. However, future large-scale studies are required to support these results.
Collapse
Affiliation(s)
| | | | | | - Hana Piroti
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mehrsa Mostafaei
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Faezeh Shaverdi
- School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | | | - Niloofar Deravi
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Minoo Roostaie
- Islamic Azad University Tehran Medical Branch, Tehran, Iran
| |
Collapse
|
2
|
Godderis L, De Ryck E, Baeyens W, Geerts L, Jacobs G, Maesen P, Mertens B, Schroyen G, Van Belleghem F, Vanoirbeek J, Van Larebeke N. Towards a more effective REACH legislation in protecting human health. Toxicol Sci 2024; 199:194-202. [PMID: 38419586 DOI: 10.1093/toxsci/kfae025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2024] Open
Abstract
There is growing evidence indicating the substantial contribution of man-made products to an increase in the risk of diseases of civilization. In this article, the Belgian Scientific Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) Committee gives a critical view on the working of REACH. The current regulatory framework needs to further evolve taking into account data generated using modern science and technology. There is a need for improved assessment process not only before but also after entering the market. Objectivity, transparency, and the follow-up after market access can be optimized. Additionally, no guidance documents exist for regulation of mixture effects. Further, the lengthiness before regulatory action is a big concern. Decision-making often takes several years leading to uncertainties for both producers and end users. A first proposed improvement is the implementation of independent toxicity testing, to assure objectivity, transparency, and check and improve compliance. A "no data, no market" principle could prevent access of hazardous chemicals to the market. Additionally, the introduction of novel testing could improve information on endpoints such as endocrine disrupting abilities, neurotoxicity, and immunotoxicity. An adapted regulatory framework that integrates data from different sources and comparing the outputs with estimates of exposure is required. Fast toxicology battery testing and toxicokinetic testing could improve speed of decision-making. Hereby, several improvements have been proposed that could improve the current REACH legislation.
Collapse
Affiliation(s)
- Lode Godderis
- Department Public Health and Primary Care, Centre for Environment and Health, Catholic University Leuven, 3000 Leuven, Belgium
- External Service for Prevention and Protection at Work, IDEWE, 3001 Heverlee, Belgium
| | - Evi De Ryck
- Department Public Health and Primary Care, Centre for Environment and Health, Catholic University Leuven, 3000 Leuven, Belgium
| | - Willy Baeyens
- Analytical, Environmental and Geo-Chemistry, VUB, 1050 Brussels, Belgium
| | - Lieve Geerts
- Flemish Institute for Technological Research, VITO, 2400 Mol, Belgium
| | - Griet Jacobs
- Flemish Institute for Technological Research, VITO, 2400 Mol, Belgium
| | - Phillippe Maesen
- Faculté de Gembloux Agro-Bio Tech, Uliège, 5030 Gembloux, Belgium
| | - Birgit Mertens
- Department of Chemical and Physical Health Risks, Sciensano, 1050 Brussels, Belgium
| | - Guy Schroyen
- Institut Scientifique de Service Public, ISSeP, 4000 Liège, Belgium
| | - Frank Van Belleghem
- Department of Environmental Sciences, Faculty of Science, Open Universiteit, 6419 Heerlen, The Netherlands
- Zoology: Biodiversity and Toxicology, Centre for Environmental Sciences, Hasselt University, 3590 Diepenbeek, Belgium
| | - Jeroen Vanoirbeek
- Department Public Health and Primary Care, Centre for Environment and Health, Catholic University Leuven, 3000 Leuven, Belgium
| | | |
Collapse
|
3
|
Bahna SL. History of food allergy and where we are today. World Allergy Organ J 2024; 17:100912. [PMID: 38800498 PMCID: PMC11126526 DOI: 10.1016/j.waojou.2024.100912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 04/23/2024] [Accepted: 04/29/2024] [Indexed: 05/29/2024] Open
Abstract
The food allergy (FA) entity went through a long difficult road which led to much delay in its recognition. After long periods of denial and misdiagnosis, it attained its current designation as food hypersensitivity or allergy. This review will briefly address the evolution of the FA entity from the early BC era until our 21st century and highlight the milestones in the main aspects of diagnosis, treatment, prevention, and research. A great recognition of the allergy specialty was gained by the discovery of its main mediator -immunoglobulin E in 1967 - which also helped in classifying FA into IgE-mediated (immediate-type) and non-IgE-mediated. The cause of the increasing prevalence during the past few decades may be attributed to an increased food consumption and the consequences of modern lifestyle (the hygiene hypothesis). In addition to a skillful medical history-taking, helpful tests have been developed involving the skin or blood. The scratch test was modified to the prick test and in certain instances prick-by-prick. The use of intradermal test has been markedly reduced. Blood testing began by measuring specific-IgE antibodies (sIgE) in the serum using the radioallergosorbent test which went through multiple modifications to avoid radioisotope material and increase the test's sensitivity. The test was advanced to measure sIgE to individual allergen components. Recently, cellular tests were developed in the form of basophil activation or mast cell activation. In most cases, FA needs verification by appropriately-designed challenge testing. Regarding treatment, strict avoidance remains the basic approach. Certain food-labeling regulations led to some improvement in the problem of hidden food allergens but more is desired. Recently some protocols for oral immunotherapy (OIT) showed reasonable safety and efficacy in preventing reactions to accidental exposures. The protocol for peanut has been approved in the United States and other foods are expected to follow. Epicutaneous immunotherapy showed higher safety and promising efficacy. Sublingual immunotherapy might follow as well. Studies on the use of certain biologicals, alone or in combination of OIT, showed promising findings. Very recently, omalizumab was approved in the United States for patients with multiple FA. A major change in the strategy of prevention is the benefit of introducing allergenic foods at an early age (4-6 months). Research on FA markedly flourished in recent decades with increasing numbers of investigators, funding, publications, and education. Despite the major strides, still more awaits exploration with expected better understanding and practice of FA.
Collapse
Affiliation(s)
- Sami L. Bahna
- Allergy & Immunology Section, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71103, USA
| |
Collapse
|
4
|
Bellanti JA, Settipane RA. Allergy and immunology: At the crossroad of inflammation and disease. Allergy Asthma Proc 2023; 44:1-2. [PMID: 36719695 PMCID: PMC9809180 DOI: 10.2500/aap.2023.44.220094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|